Compare Nuscale Power Corporation (SMR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs BIO-TECHNE Corp — how do they compare? Nuscale Power Corporation trades at $9.63 (market cap $3.77B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 3× Nuscale Power Corporation's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| SMR | TECH | |
|---|---|---|
Market Cap | $3.77B | $11.24B |
Sector | Utilities | Health |
52-Week High | $53.43 | $72.29 |
52-Week Low | $7.59 | $43.31 |
Enterprise Value | $2.70B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NuScale Power (SMR) trades at $9.83, up 3.69% with a bullish technical signal. The company reported Q2 2026 earnings that met estimates but revenues plunged 98.8% as RoPower work wound down. Despite negative profit margins and cash burn, NuScale maintains $1.9 billion liquidity and is advancing commercialization of its NRC-approved small modular reactor technology amid growing AI power demand.
The outlook hinges on successful commercial deployment of SMR technology, with potential for significant upside if large-scale projects materialize. Key risks include execution challenges, revenue volatility, and intense competition in the nuclear energy sector. Analyst consensus suggests 8% upside to the $10.63 price target, but investors should weigh the high-risk, high-reward nature of this pre-revenue growth story.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
